Press Releases Palisade Bio, Inc.

Equities

SNCA

US6963894026

Delayed Nasdaq Other stock markets 09:44:10 15/05/2024 pm IST			5-day change	1st Jan Change
6.446 ^USD	+3.30%		-8.70%	-27.16%

10/05	Palisade Bio, Inc. announced that it has received $3.999943 million in funding	CI
07/05	Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update	14/05	AQ
Palisade Bio Appoints Margery Fischbein to its Board of Directors	07/05	AQ
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules	02/05	AQ
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)	01/05	AQ
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	24/04	AQ
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23/04	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	17/04	AQ
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	16/04	AQ
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	11/04	AQ
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	10/04	AQ
Palisade Bio Announces 1-for-15 Reverse Stock Split	04/04	AQ
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update	27/03	AQ
Palisade Bio to Present at Digestive Disease Week (DDW) 2024	15/02	AQ
Palisade Bio Provides Corporate Update and Reiterates Guidance	13/02	AQ
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members	09/02	AQ
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders	08/02	AQ
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million	30/01	AQ
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress	29/01	AQ
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress	09/01	AQ
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108	29/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Palisade Bio, Inc.

Equities

SNCA

US6963894026

Press Releases

Filters